Table 1.

Baseline demographics of the study population (n = 266)a

OverallControlRaloxifene 60 mgRaloxifene 30 mgLovaza 4 gLovaza 4 g + raloxifene 30 mg
Demographic(n = 266)(n = 53)(n = 53)(n = 53)(n = 54)(n = 53)Overall difference P
Age (years)57.46 ± 5.6657.11 ± 5.958.15 ± 5.0957.68 ± 5.156.56 ± 6.957.85 ± 5.10.612
BMI (kg/m2)26.12 ± 5.0326.54 ± 5.826.05 ± 5.49b26.16 ± 4.46b25.71 ± 4.926.17 ± 4.5b0.946
Waist:hip ratio0.81 ± 0.090.81 ± 0.080.80 ± 0.08b0.81 ± 0.07b0.80 ± 0.070.820 ± 0.13b0.815
Number of births0.208
 050 (19%)8 (15%)9 (17%)9 (17%)12 (22%)12 (23%)
 137 (14%)7 (13%)7 (13%)9 (17%)9 (17%)5 (9%)
 281 (30%)13 (25%)21 (40%)14 (26%)16 (30%)17 (32%)
 ≥398 (37%)25 (47%)16 (30%)21 (40%)17 (31%)19 (36%)
Age at first child birth (years)25.93 ± 5.12 (n = 205)24.3 ± 4.0 (n = 44)26.4 ± 4.8 (n = 41)26.6 ± 6.5 (n = 42)27.1 ± 5.1 (n = 40)25.4 ± 4.7 (n = 38)0.105
Family history of breast cancer140 (53%)26/53 (49%)26/53 (49%)26/53 (49%)33/54 (61%)29/53 (55%)0.634
History of prior breast biopsy95 (36%)14/53 (26%)20/53 (38%)26/53 (49%)15/54 (28%)20/53 (38%)0.107
  • aData represent mean ± SD.

  • bOne subject in each of these groups did not get anthropometric measurements.